Skip to main content
S

SHAANXI KANGHUI PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 603139 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 929 across all filing types
Latest filing 2026-05-08 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603139

About SHAANXI KANGHUI PHARMACEUTICAL CO., LTD

Shaanxi Kanghui Pharmaceutical Co., Ltd. specializes in the research, development, production, and distribution of a diverse range of pharmaceutical products. The company focuses on modernizing traditional Chinese medicine while also manufacturing chemical drugs and health-related products. Its therapeutic portfolio primarily addresses cardiovascular and cerebrovascular diseases, respiratory conditions, and gynecological health. By integrating advanced pharmaceutical technologies with traditional medicinal knowledge, the company provides treatment solutions across various dosage forms, including capsules, tablets, and granules. Its operations encompass the entire value chain from raw material sourcing and extraction to final product formulation and marketing, emphasizing quality control and innovation in drug delivery systems.

Recent filings

Filing Released Lang Actions
康惠股份关于控股股东部分股份质押的公告
Regulatory Filings
2026-05-08 Chinese
康惠股份2026年度向金融机构申请综合授信额度及接受关联方担保的公告
Capital/Financing Update Classification · 91% confidence The document is an official announcement by the company’s board concerning the application for a new credit facility (up to RMB25 billion) from financial institutions and the acceptance of related-party guarantees. This clearly pertains to financing activities and credit arrangements, fitting the Capital/Financing Update category. It is neither a shareholder voting result, an earnings report, nor an annual or interim report. Hence, the appropriate classification is CAP.
2026-04-23 Chinese
康惠股份关于计提信用减值损失及资产减值损失的公告
Regulatory Filings Classification · 80% confidence The document is an official Chinese A-share regulatory announcement (“公告”) by the board of Shaanxi Kanghui Pharmaceutical detailing the provision for credit impairment losses and asset impairment losses for fiscal year 2025. It includes board and audit committee approvals, accounting policies applied, breakdowns of impairment amounts, and the impact on consolidated profit. It is not a full Annual or Interim Report, not an Earnings Release (no summary of period results), not a dividend, financing, M&A, or management change announcement. It is also not merely a notification that a report is published—it is the substantive disclosure itself. Therefore, it falls under the general fallback category for miscellaneous regulatory filings.
2026-04-23 Chinese
康惠股份2025年度内控审计报告
Audit Report / Information Classification · 90% confidence The document is an internal control audit report issued by a registered accounting firm for the fiscal year ending December 31, 2025. It contains the auditor’s responsibilities, scope, opinion on the effectiveness of financial-reporting internal controls, report codes, and sign-off pages. This is a standalone audit report (not a full annual report), matching the “Audit Report / Information” category.
2026-04-23 Chinese
康惠股份接受关联方财务资助的公告
Capital/Financing Update Classification · 90% confidence The document is an official corporate announcement detailing the terms, counterparties, amounts, and approvals for new financing (related-party loans) to fund daily operations. It is not a full annual or interim report, not a share issuance or delisting notice, and not an earnings call transcript. It specifically updates on the company’s financing activity, matching the “Capital/Financing Update” category.
2026-04-23 Chinese
康惠股份董事和高级管理人员薪酬管理制度
Governance Information Classification · 85% confidence The document is an internal policy manual titled “董事和高级管理人员薪酬管理制度” (Board and Senior Management Remuneration Management System) issued by a Chinese listed company. It outlines governance structures, committees, and detailed remuneration policies for directors and senior executives. It is not an earnings release, financial report, or announcement of a report; rather, it describes the company’s internal governance rules and practices regarding compensation. This aligns with the definition of Governance Information (CGR).
2026-04-23 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.